Arab Health Exhibition is the largest and most comprehensive gathering for healthcare industry in the MENA (Middle East and North Africa) region.
Arab Health got an auspicious start as the First Exhibition of Singclean in 2019.
During the exhibition between 28th – 31st in January 2019, Singclean has meeting over 100 visitors including distributors and professors from the Middle East, Africa, Europe and Asia, etc.
Singclean launched new product: Hyaderm, make an impression and got an excellent results.
Singclean People are faithful to the original aspiration and continue marching forward: To be the Leading Manufacturer of the Most Complete Varieties Of Absorbable Biomaterials in China.
-
singclean | 2019-02-14Headlining FIGO 2025: A Can’t-Miss Keynote by Prof. Osama Shawki, Presented by Singclean & KSMSingclean, in partnership with Kayan Al-Seha Medical (KSM), will debut at FIGO 2025 in Cape Town with a keynote lecture by renowned gynecologist Professor Osama Shawki. His session will spotlight innovations in hysteroscopy and adhesion prevention, showcasing Singclean’s commitment to advancing women’s healthcare worldwide.
-
singclean | 2019-02-14Singclean Draws Major Attention at ESCRS 2025 with Advanced Viscoelastic Solution for Ophthalmic SurgeryCOPENHAGEN, DENMARK – Hangzhou Singclean Medical Products Co., Ltd. made a strong impression at the 45th ESCRS Congress (European Society of Cataract and Refractive Surgeons), held September 12–16, 2025, at the Bella Center in Copenhagen. Recognized globally for its high professional standards and influence in ophthalmology, the congress gathered leading industry manufacturers, surgeons, and specialists from around the world.
-
singclean | 2019-02-14Singderm Filler Achieves 92.7% Efficacy at 12 Months in Global Clinical Trial, Validated by Landmark Thailand MasterclassBangkok, Thailand – Singderm, a globally certified dermal filler brand, has demonstrated unprecedented clinical performance in its Thailand Masterclass led by renowned physician Dr. Worawat Nolah. Three top KOLs (Hack Anantaya, Chalidaorn PinNy, Thantaya Thuranuch) received multi-zone injections with zero complications, reinforcing Singderm’s 92.7% 12-month efficacy rate from a 100-subject clinical trial.